Aldevron, Ginkgo Bioworks achieve mRNA manufacturing breakthrough

By The Science Advisory Board staff writers

August 10, 2021 --

Aldevron and partner Ginkgo Bioworks said that their strategic partnership has led to a manufacturing breakthrough for an enzyme often used in manufacturing mRNA therapies and vaccines.

The two companies, which have been working together since early 2021 to optimize the production of mRNA vaccine components, said they have achieved an over 10 times more efficient manufacturing process for the vaccinia capping enzyme. Aldevron holds the exclusive rights to the protocol conditions of the newly developed manufacturing process.


Copyright © 2021 scienceboard.net
 


MemberID or email address:

Password:
Forgot your password?